is compound tirzepatide fda approved Says Compounded Must Exit the Market Joi + Blokes Zepbound 2026:

Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts

For many struggling with weight loss, finding an effective solution can feel like an uphill battle

Many users report common mild symptoms clearing up within a couple of weeks

This typically means switching to a stronger medication or making dietary or exercise changes, although these measures do not always resolve the plateau

Backed by trusted medical expertise and community reputation

Entities may only sell compounded drugs that are identical to an FDA-approved drug when that drug is on the FDA drug shortage list